AMAZENTIS
23.1.2020 21:58:10 CET | Business Wire | Press release
Amazentis announces the debut of Timeline , a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland. Given the increase in the aging population globally -- according to a 2019 Deutsche Bank study , there are more people on Earth older than sixty five than younger than five for the first time -- it is imperative for consumers to take proactive measures to maintain a high quality of life, for as long as they live.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005820/en/
Timeline contains the proprietary nutrient Mitopure ™, a highly pure form of Urolithin A. After a decade of rigorous research by leading scientists around the world, Mitopure has been shown to help counter age-associated cellular and muscular decline by revitalizing the mitochondria, the powerplants of our cells.
Timeline will be the first consumer product in the world to contain precisely calibrated doses of Mitopure that have been clinically shown to improve the mitochondrial and cellular health of the skeletal muscle. Timeline will be available to purchase online for consumers in the United States in the first half of 2020 at www.timelinenutrition.com .
“After a decade of research and trials to perfect Mitopure, we’re giving consumers access to a product that improves their muscle health by targeting aging mitochondria,” said Amazentis CEO and Co-Founder, Chris Rinsch.
“For years, consumers have been searching for a solution to maintain muscle health as they age; Timeline provides a new way to proactively take control of cellular health early on, which directly impacts the aging process,” added Amazentis Co-Founder and Chairman Patrick Aebischer.
The World Economic Forum engages societal leaders to shape global, regional and industry agendas. As part of the Forum, there will be a panel discussion on January 23rd at 15:00 CET at the House of Switzerland, focusing on the innovations in the food and nutrition industry. During the conversation, Rinsch will share the health benefits of Timeline and Mitopure with the audience. The panel will be moderated by CNN Money Switzerland Anchor Anna Maria Montero and include:
- Nestlé Global Chairman of the Board, Paul Bulcke
- École Polytechnique Fédérale de Lausanne (EPFL) President, Martin Vetterli
- 3 Star Michelin Chef, Hôtel de Ville de Crissier, Franck Giovannini
- Amazentis CEO and Co-Founder, Chris Rinsch
Amazentis is an innovative life sciences company pioneering scientific breakthroughs in nutrition to manage health conditions linked to aging. The company’s lead ingredient, Mitopure™, has been favorably reviewed by the U.S. Food and Drug Administration (FDA) following a GRAS (generally recognized as safe) filing. Mitopure has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation.
About Timeline
Timeline is a novel nutrition brand developed by Amazentis on the belief that uncompromising research can unlock a new class of nutrition that is backed by cutting edge science. As scientists, we know that physical decline from aging can’t be stopped. However, through its groundbreaking science, Timeline is committed to developing products designed to help reduce the impact of time on health. For more information, please visit timelinenutrition.com
.
About Mitopure
Mitopure is a highly pure form of Urolithin A, a bioactive dietary metabolite that is naturally produced when eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, leading to the growth of healthy mitochondria. For more information, please visit https://www.mitopure.com/
.
About Amazentis
Amazentis is an innovative life science company that employs today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. For more information on Amazentis, please visit www.amazentis.com
.
Related Links
https://www.timelinenutrition.com
https://www.mitopure.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200123005820/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 09:00:00 CEST | Press release
ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup
Regnology Research Maps Route From AI Pilots to Production in Regulatory Reporting22.9.2026 08:33:00 CEST | Press release
Global study of 276 practitioners across 22 countries defines the “Agentic Gap” and outlines how financial institutions can transition from experimentation to governed, high-impact deployment.Supporting analysis by Oliver Wyman finds reporting absorbs 1% to 3% of total bank expenditure, with a concentrated share of it addressable by agentic workflows. Regnology, a leader in regulatory, risk, tax and finance reporting technology, today published “The Agentic Gap: From Control to Intelligence in Regulatory Reporting”, accompanied by a video foreword from Chief Executive Officer Rob Mackay. The global study sets out where agentic AI can take on meaningful operational load today, and gives institutions a practical roadmap from isolated pilots into scaled production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921218912/en/ The research finds an industry already mobilizing. 87% of respondents are exploring, piloting or embe
Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 20281 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements:Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio
OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 07:00:00 CEST | Press release
New portfolio combines high-performance cell culture media, molecule-specific CQA optimization, and integrated CDMO capabilities to help biosimilar developers accelerate the path to analytical similarity and improve process economics. OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of
H2SITE Secures €3.4 Million (NOK 39.1 million) in Enova Funding to Scale Onboard Ammonia-To-Power for Commercial Maritime Applications22.9.2026 06:00:00 CEST | Press release
The 700 kW system builds on H2SITE’s previous maritime deployments and is designed as a modular, replicable solution for auxiliary power onboard vessels H2SITE has secured €3.4 million (NOK 39.1 million) in funding from Enova for HydraNord Power, a project that will develop and validate a commercial-scale onboard ammonia-to-power system for the maritime sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921324898/en/ Enova is one of the Norwegian government's primary instruments for accelerating the country's climate and energy transition. Its primary responsibility is to manage the Climate and Energy Fund on behalf of the Norwegian government. For H2SITE, Enova’s support is a major milestone in the commercialisation of its onboard ammonia cracking technology, enabling the company to scale from proven maritime demonstrations to replicable commercial solutions for the global shipping industry. Led by H2SITE, HydraNord
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom